AN2 Therapeutics Inc (ANTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.05 (+3.06%), Market cap $0.18B, 52-week low–high $1.03 ~ $5.46.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It ha
Financial statements, price targets, institutional (13F) holdings and related news for AN2 Therapeutics Inc are updated in real time on BlackAll Trade.
AN2 Therapeutics Inc trades at $5.05 (+3.06%). Real-time quotes and charts are available on BlackAll Trade.
AN2 Therapeutics Inc has a market cap of about $0.18B.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 cl